Chinook Therapeutics, Inc.
KDNY
Price:
$40.39
Market Cap:
$2.71B
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headq...[Read more]
Industry
Biotechnology
IPO Date
2020-10-06
Stock Exchange
NASDAQ
Ticker
KDNY
The ROE as of September 2024 (TTM) for Chinook Therapeutics, Inc. (KDNY) is -57.70%
According to Chinook Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -57.70%. This represents a change of 292.76% compared to the average of -14.69% of the last 4 quarters.
Chinook Therapeutics, Inc. (KDNY) Historical ROE (quarterly & annually)
How has KDNY ROE performed in the past?
The mean historical ROE of Chinook Therapeutics, Inc. over the last ten years is -17.35%. The current -57.70% ROE has changed 232.54% with respect to the historical average. Over the past ten years (40 quarters), KDNY's ROE was at its highest in in the December 2021 quarter at 1.66%. The ROE was at its lowest in in the September 2020 quarter at -42.10%.
Average
-17.35%
Median
-31.54%
Minimum
-70.47%
Maximum
113.94%
Chinook Therapeutics, Inc. (KDNY) ROE by Quarter and Year
Discovering the peaks and valleys of Chinook Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 167.66%
Maximum Annual ROE = 113.94%
Minimum Annual Increase = -261.68%
Minimum Annual ROE = -70.47%
| Year | ROE | Change |
|---|---|---|
| 2022 | -41.77% | 87.07% |
| 2021 | -22.33% | -8.45% |
| 2020 | -24.39% | -121.41% |
| 2019 | 113.94% | -261.68% |
| 2018 | -70.47% | 82.18% |
| 2017 | -38.68% | -3.57% |
| 2016 | -40.11% | 167.66% |
Chinook Therapeutics, Inc. (KDNY) Average ROE
How has KDNY ROE performed in the past?
The current ROE of Chinook Therapeutics, Inc. (KDNY) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-29.50%
5-year avg
-9.01%
10-year avg
-17.35%
Chinook Therapeutics, Inc. (KDNY) ROE vs. Peers
How is KDNY’s ROE compared to its peers?
Chinook Therapeutics, Inc.’s ROE is greater than DICE Therapeutics, Inc. (-102.37%), greater than Pliant Therapeutics, Inc. (-41.05%), greater than Crinetics Pharmaceuticals, Inc. (-62.63%), less than Ascendis Pharma A/S (251.76%), greater than Ventyx Biosciences, Inc. (-61.43%), greater than Nuvalent, Inc. (-28.83%), greater than Cerevel Therapeutics Holdings, Inc. (-98.94%), greater than Travere Therapeutics, Inc. (-102.43%), greater than Structure Therapeutics Inc. (-20.15%), greater than Avidity Biosciences, Inc. (-32.89%), greater than Revolution Medicines, Inc. (-34.57%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than SpringWorks Therapeutics, Inc. (-56.13%), greater than Arcellx, Inc. (-12.42%), greater than Vaxcyte, Inc. (-30.07%), greater than Viridian Therapeutics, Inc. (-49.65%), greater than KalVista Pharmaceuticals, Inc. (-97.37%), greater than Theseus Pharmaceuticals, Inc. (-24.51%), greater than Kura Oncology, Inc. (-40.43%),
| Company | ROE | Market cap |
|---|---|---|
| -102.37% | $2.27B | |
| -41.05% | $782.51M | |
| -62.63% | $4.03B | |
| 251.76% | $6.83B | |
| -61.43% | $153.35M | |
| -28.83% | $5.59B | |
| -98.94% | $8.19B | |
| -102.43% | $839.88M | |
| -20.15% | $2.11B | |
| -32.89% | $4.74B | |
| -34.57% | $6.99B | |
| -122.70% | $1.25B | |
| -56.13% | $2.88B | |
| -12.42% | $3.83B | |
| -30.07% | $12.45B | |
| -49.65% | $900.21M | |
| -97.37% | $531.63M | |
| -24.51% | $181.50M | |
| -40.43% | $1.48B |
Build a custom stock screener for Chinook Therapeutics, Inc. (KDNY) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Chinook Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Chinook Therapeutics, Inc. (KDNY) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Chinook Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Chinook Therapeutics, Inc.'s ROE?
How is the ROE calculated for Chinook Therapeutics, Inc. (KDNY)?
What is the highest ROE for Chinook Therapeutics, Inc. (KDNY)?
What is the 3-year average ROE for Chinook Therapeutics, Inc. (KDNY)?
What is the 5-year average ROE for Chinook Therapeutics, Inc. (KDNY)?
How does the current ROE for Chinook Therapeutics, Inc. (KDNY) compare to its historical average?